Premier Alternatives

Azalea Therapeutics

Biotechnology · Berkeley, CA · Founded 2023 · Privately Held (backing)

Operator of a biotechnology platform intended to enable precise genome editing inside the body for disease treatment. Azalea Therapeutics is based in Berkeley, CA and was founded in 2023. It was valued at $153 million at its early-stage round in Oct 2025, the last priced event on record. It has raised $82 million across 1 recorded round; the latest was a $65 million Series A in Oct 2025.

PMV mark · valuation
$153.0M
Oct 2026
Priced at
its early-stage round
Oct 2025
Total raised
$82.0M
Last round
Early Stage VC (Series A)
Oct 2025

Azalea Therapeutics key facts

as of Oct 2026
  • Operator of a biotechnology platform intended to enable precise genome editing inside the body for disease treatment.
  • Azalea Therapeutics is valued at approximately $153.0M as of Oct 2026, set at its early-stage round, Oct 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $82.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($65.0M) in Oct 2025.
  • Notable investors include RA Capital Management, University of California, Sozo Ventures, Third Rock Ventures, Berkeley — 6 tracked in total.
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$153.0M

Valued at $153.0M at its early-stage round, Oct 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Azalea Therapeutics with a free account
  • ·Watch Azalea Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Azalea Therapeutics funding rounds

1 rounds
Oct 2025Early Stage VC (Series A)$65.0M▮
Full funding history →

Azalea Therapeutics valuation

Azalea Therapeutics was valued at $153 million at its early-stage round in Oct 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Azalea Therapeutics raised?

Azalea Therapeutics has raised $82 million in total; 1 of its rounds is on record. The largest on record was a $65 million Series A in Oct 2025.

Azalea Therapeutics investors

6 investors are on record for Azalea Therapeutics, including RA Capital Management, University of California, Sozo Ventures and Third Rock Ventures. The Series A in Oct 2025 drew 3 investors.

Comparable companies

Comparable biotechnology names by valuation on PrivateMarketView: Ambros Therapeutics ($250 million), Gameto ($243 million) and Antheia ($240 million).

About Azalea Therapeutics

Operator of a biotechnology platform intended to enable precise genome editing inside the body for disease treatment. The company offers an Enveloped Delivery Vehicle technology that directs CRISPR-Cas9 cargo to specific cells, enabling patients with cancer, autoimmune, and genetic conditions to receive targeted and sustained therapies.

Industry
Biotechnology
Sector
Healthcare
HQ
Berkeley, CA, United States
Founded
2023
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.